1, oxitinib;
2.Renvartinib
3. Dalafeni;
4. trimetinib;
5. Ze Boutigny;
6. Olapari;
7. Ni Rapali;
8. Enotinib;
9. Desuzumab;
10, amitinib;
1 1, cetuximab;
12，Initutuzumab
13, flumatinib;
14, fulvestrant;
15, enzalutamide;
16, paclitaxel liposome for injection;
17, albumin paclitaxel;
18, oxaliplatin mannitol.
Some of them have medical insurance, but most of them still don't.
It is understood that by the end of last year, the proportion of urban workers' basic medical insurance and urban residents' medical insurance participation in Hunan exceeded 98%, the proportion of reimbursement within the basic medical insurance policy for urban workers was 82%, and the proportion of urban residents' medical insurance reimbursement was 63%.
According to Professor Hu Chunhong, director of the Cancer Center of the Second Xiangya Hospital of Central South University, before the negotiation of serious illness medical insurance drugs in Hunan in 2006, most lung cancer patients in our province received chemotherapy, and the utilization rate of targeted drugs was very low, because targeted drugs were expensive and self-funded. Some patients buy generic drugs with different quality through unknown channels, which brings great risks to the safety of patients' treatment.
"The adjustment of the medical insurance catalogue has effectively reduced the financial burden of patients and enabled lung cancer patients to be treated with peace of mind." Hu Chunhong said that targeted drugs are included in the provincial medical insurance reimbursement category, and patients pay 40-80 yuan per day at their own expense. The overall treatment cost is lower than that of chemotherapy, with fewer side effects and better quality of life for patients.
Original study on targeted drugs changing the treatment strategy of lung cancer
With the rising incidence, lung cancer has become the first fatal cancer in Hunan Province. In recent years, with the continuous development of precision medicine, targeted therapy has brought new hope to lung cancer patients. It has been found that targeted therapy is obviously superior to chemotherapy for advanced non-small cell lung cancer with EGFR gene mutation.
At present, the first generation TKI targeted drugs have become the first-line standard therapeutic drugs recommended by various clinical guidelines at home and abroad. In this adjustment, a generation of EGFR-TKI lung cancer targeted drugs were included in the medical insurance catalogue. Professor Hu Chengping, director of the Department of Respiratory Medicine, Xiangya Hospital of Central South University, said that in China, patients with non-small cell lung cancer account for about 85% of the total number of lung cancer cases, and about 30%-40% of them will have EGFR gene mutations. Under the standard treatment of targeted drugs such as gefitinib, the survival time of patients will be greatly prolonged, and the side effects of targeted therapy are significantly less than chemotherapy, and the quality of life will be improved accordingly.
Legal basis: People's Republic of China (PRC) Social Insurance Law.
Twenty-eighth medical expenses that meet the basic medical insurance drug list, diagnosis and treatment items, medical service facilities standards and emergency treatment and rescue shall be paid by the basic medical insurance fund in accordance with state regulations.
Twenty-ninth medical expenses of the insured shall be paid by the basic medical insurance fund, and shall be directly settled by the social insurance agency, medical institutions and pharmaceutical business units.
The administrative department of social insurance and the administrative department of health shall establish a settlement system for medical expenses in different places to facilitate the insured to enjoy the basic medical insurance benefits.